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Sevoflurane vs propofol in 
high risk cardiac surgery: 
design of the randomized 
trial “Sevo-Aifa”
ABSTRACT
Objective. Recent evidence indicates that volatile anesthetics improve post-ischemic recovery. In a meta-analysis of 22 
randomized studies, the use of volatile anesthetics was associated with significant reduction in myocardial infarction and 
mortality. All the studies in this meta-analysis included low risk patients undergoing isolated procedures (mostly isolated 
coronary artery bypass grafting). We want to confirm the cardioprotective effects of volatile anesthetics, in cardiac surgery, 
as indicated by a reduced intensive care unit stay and/or death in a high risk population of patients, undergoing combined 
valvular and coronary procedures. 
Methods. Four centres will randomize 200 patients to receive either  total intravenous anesthesia with propofol or  anesthesia 
with sevoflurane. All patients will receive a standard average  dose of opiates. Perioperative management will be otherwise 
identical and standardized. Transfer out of the intensive care unit will  follow standard criteria.
Results. Reduced cardiac damage will probably translate into better tissue perfusion and faster recovery, as documented 
by a reduced intensive care unit stay. The study is powered to detect a reduction in the composite end point of prolonged 
intensive care unit stay (>2days) and/or death from 60% to 40%. 
Conclusions. This will be the first multicentre randomized controlled trial comparing the effects of volatile anesthetics and 
total intravenous anesthesia in high risk patients undergoing cardiac procedures. Our trial should help clarify whether or 
not volatile agents should be recommended in high risk patients undergoing cardiac surgery.
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Introduction
Approximately one million cardiac sur-
gery procedures are performed each 
year worldwide. These procedures are 
burdened by a significant risk of myo-
cardial damage: this, in turn, can pro-
long intensive care unit stay as well as 
increase perioperative mortality rate.
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The American College of Cardiology / 
American Heart Association Guidelines 
suggest considering, in the periopera-
tive plan, anesthetic techniques and 
drugs that have known cardiac ben-
efit. (1) The decision between different 
types of anesthesia is demanded to 
the anesthesia care team, because 
there is no proven myocardium protec-
tive anesthetic technique. (2,3) Up until 
now , no anesthetic  drug or technique 
has been proven  to reduce periopera-
tive morbidity and mortality in cardiac 
surgery.
Volatile anesthetics improve post-
ischemic recovery at the cellular level, 
in isolated hearts, and in animals, 
(4,5) both through a pharmacologi-
cal preconditioning and postcondition-
ing action. (6,7) Till recently there was 
no evidence that the cardioprotective 
effects of volatile anesthetics are appli-
cable to  clinical settings and are asso-
ciated with improved cardiac function, 
ultimately resulting in a better outcome 
in patients undergoing cardiac surgery. 
(8,9)
A recent meta-analysis (10) summa-
rized 22 randomized trials including 
1922 patients (904 randomized to total 
intra-venous anesthesia (TIVA) and 
1018 receiving desflurane or sevoflu-
rane in their anesthesia plan). Signifi-
cant reductions in myocardial infarc-
tions (24/979 (2.4%) were found in the 
volatile anesthetics group vs 45/874 
(5.1%) the control arm, odds ratio (OR) 
= 0.51 (0.32-0.84), p = 0.008, and p 
for heterogeneity = 0.77) and mortality 
(4/977 (0.4%) vs 14/872 (1.6%), OR = 
0.31 (0.12-0.80), p = 0.02, and p for 
heterogeneity = 0.88). This was the first 
time that the choice of an anesthetic 
regimen seemed to have an impact 
on patients’ outcome following car-
diac surgery. All but one of the 22 ran-
domized controlled studies included 
in the meta-analysis studied low risk 
patients undergoing isolated proce-
dures (mostly coronary artery bypass 
grafting). 
Studies performed on patients under-
going coronary artery bypass graft 
(CABG) surgery, either with cardiopul-
monary bypass (CPB) (11-13) or on the 
beating heart, (14-16) showed lower 
postoperative values of cardiac tro-
ponin as a result of the cardioprotective 
effect of volatile anesthetics. At present, 
cardiac troponin is the most popular 
biomarker for myocardial damage, with 
nearly total myocardial tissue specifi-
city and extreme sensitivity, reflecting 
even a very small amount of myocardial 
necrosis. (17)
Few and discordant results exist for val-
vular surgery. In Landoni et al. (18) myo-
cardial damage measured by cardiac 
troponin release was not reduced by 
volatile anesthetics in patients undergo-
ing mitral valve surgery. Cromheecke 
et al. (19) showed that an anesthetic 
plan with sevoflurane was associated 
with better preservation of cardiac func-
tion and lower cardiac troponin release 
peak in patients undergoing aortic valve 
replacement for aortic stenosis. 
Large multicentre randomized control-
led studies in high risk populations of 
patients are needed to evaluate the 
possible influence of different anes-
thetic regimens on patient outcomes 
after cardiac surgery. Clinical impli-
cation could be extended to patients 




Patients with concomitant valvular and 
coronary artery disease undergoing 
elective cardiac surgery in four teaching 
hospitals will be enrolled. All patients 
will be admitted to the main ward before 
the operation, will undergo cardiac sur-
gery under general anesthesia (the ran-
domization and administration of the 
study drugs will be performed in the 
operating theatre) and then transferred 
to the intensive care unit (ICU). 
The study will start after Ethical Com-
mittee approval is received Consecu-
tive patients who give written informed 
consent, aged 18 years or older, will be 
enrolled over a 2 year period. 
Conversely, the following exclusion cri-
teria will be applied: ongoing acute 
myocardial infarction, cardiac troponin 
>1 ng/ml, previous unusual response 
to an anesthetic, use of sulfonylurea, 
theophylline or allopurinol, thoracot-
omy.
Study procedure
In this randomized multicentre con-
trolled study, the study group will 
receive sevoflurane (Sevorane, Abbott) 
0.5-2 Minimal Alveolar Concentration 
(MAC) equal to 1-4% for a 4-6 hour 
period throughout the procedure (from 
anesthesia induction to transfer to the 
ICU). The control group will receive pro-
pofol (Diprivan, Astra Zeneca) 2-3 mg/
kg/h for the same 4-6 hour period. This 
drug represents the standard hypnotic 
drug used in most cardiac anesthesia 
units. (20)
All pre-operative medications will rou-
tinely be omitted on the day of surgery. 
Pre-operative beta-blockers will be 
continued post-operatively if permitted 
based on heart rate, blood pressure 
and cardiac index evaluation. No other 
drugs will be continued routinely nor 
given for cardiac protection.
All patients will be premedicated with 
morphine 0.1 mg/kg and scopo-
lamine 0.25 mg i.m. one hour before 
surgery. During anesthesia induction 
each patient will receive an intrave-
nous bolus of hypnotics, opioids, and 
a muscle relaxant. Standard monitoring 
will include invasive radial artery blood 
pressure measurement, continuous 
ECG with ST segment monitoring, pulse 
oximetry, central venous pressure, 
capnometry and urine output. Trans-
esophageal echocardiography will be 
used in all patients at CPB weaning and 
a pulmonary artery catheter will be used 
as indicated by the attending physician, 
but data will not be collected.
Anesthesia will be maintained with 
opioids, muscle relaxants and either 
sevoflurane or propofol for all the pro-
cedures, as described above, starting 
immediately after intubation.
All patients will receive an intraopera-
tive infusion of tranexamic acid: 1g in 
20 minutes followed by a 400 mg/h 
infusion.
CPB will be conducted at moderate 
hypothermia (32-34 °C) with myocardial 
protection during aortic cross clamping 
obtained by antegrade and/or retro-
grade cold blood cardioplegia. Acti-
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vated clotting time will be maintained 
greater than 480 seconds for CPB, the 
effect of heparin (starting dose = 3 
mg/kg) will be reversed with protamine 
sulphate in a 1 to 1 ratio. If the target 
mean arterial pressure of 65 mmHg is 
not achieved, despite volume loading 
to a central venous pressure of 10 cm 
H2O after weaning from CPB, an infu-
sion of dopamine (initial dose 5 g/kg/
min) will be started. Following surgery, 
patients will be transferred to the ICU, 
sedated with propofol for 4 hours and 
weaned from the ventilator as soon 
as hemodynamic stability- with no 
major bleeding, normothermia, and 
an adequate level of consciousness 
and pain control- is achieved. Post-
operative pain relief will be provided to 
all patients by boluses of intravenous 
morphine. Blood pressure (systolic, 
mean and diastolic), heart rate and 
central venous pressure will be record-
ed at 7 time points: before induction 
of anesthesia, before and after cardi-
opulmonary bypass, upon  ICU arrival 
and 4, 8 and 12 hours later. Myocardial 
infarction will be diagnosed on ECG, 
biochemical and echocardiographic 
findings. 
Transfer out of the ICU will be performed 
with SpO2 94% or greater at an FiO2 
of 0.5 or less by facemask, adequate 
cardiac stability with no hemodynami-
cally significant arrhythmias, chest tube 
drainage less than 50 ml/h, urine output 
greater than 0.5 ml/kg/h, no intrave-
nous inotropic or vasopressor therapy 
in excess of dopamine 5 g/kg/min, 
and no seizure activity. Particular care 
will be taken to ensure that all patients 
will be actually discharged the moment 
they meet the criteria for discharge from 
the ICU. Times of fitness for discharge 
criteria will be noted and compared to 
the actual discharge times. 
A register of the patients screened but 
not enrolled will be kept. Patients will 
sign the written informed consent the 
day before surgery but the envelopes 
with the randomization will be opened 
immediately before the beginning of 
anesthesia. Subjects will be allocated 
using a centralized randomization sys-
tem derived from a computer-gener-
ated list of random numbers. Stratifi-
cation per participating centre will be 
performed. All study personnel, includ-
ing those involved in  ICU management 
will be blinded to treatment assignment 
for the duration of the study, except for 
the cardiac anesthesiologists in  the 
operating room who will not be involved 
in data collection, data entry or data 
analysis. To further reduce bias, data 
will be collected by trained observers 
who will not participate in patient care 
and who will be blinded to the anes-
thetic regimen. Data collection will end 
at ICU discharge. No interim analyses 
will be carried out during the course of 
this study.
Clinical end points and follow up
In the present study we will test the 
hypothesis that volatile anesthetics 
reduce cardiac damage and allow bet-
ter tissue perfusion and faster recovery. 
The primary end point of the study will 
be a composite end point: death and/
or reduction in prolonged intensive care 
unit stay (defined as > 2 days). 
Secondary end points will be repre-
sented by cardiac troponin release (ng/
ml, either the peak value or the area 
under the curve); incidence of periop-
erative myocardial infarction (based 
on ECG, troponin values and clinical 
criteria); duration of mechanical venti-
lation (hours); postoperative hospital 
stay (days, in particular a prolonged 
hospital stay defined as > 7 days will 
be investigated).
Caregivers will be interviewed daily 
for the occurrence of postoperative 
adverse events. Clinical follow up will 
be performed before hospital dis-
charge (length of hospital stay, major 
complications). Follow up by phone 
will be performed at 30 days and at 1 
year and will focus on adverse cardiac 
events and hospital readmissions. We 
do not expect to lose any patients prior 
to hospital discharge. Default rate at 30 
days and 1 year will be acknowledged 
in the paper.
Statistical analysis and sample size 
estimates
An independent clinical  investigator 
with extensive experience in designing, 
conducting and analysing clinical trials, 
and who will not be involved in pati-
ent management, will be responsible 
for the statistical analysis. Data will 
be stored electronically and analysed 
using Epi Info 2002 (CDC), SPSS 11.0 
(SPSS), and STATA 9.0 (STATA) sof-
twares, where appropriate. All data 
analysis will be carried out according 
to a pre-established intention-to-tre-
at analysis plan. Dichotomous data 
(including the primary outcome) will be 
compared by using a two-tailed c2 test 
with the Yates correction or Fisher’s 
exact test when appropriate. Continu-
ous measurements will be compared 
using the Mann-Whitney U test. Two-
sided significance tests will be used 
throughout. Data will be presented as 
medians (25th and 75th percentiles) or 
as means (+ standard deviation –SD).
Sample-size calculation will be based on 
a two-sided alpha error of 0.05 and 80% 
power. On the basis of our experience 
investigating ICU stay and mortality 
after valvular surgery we anticipate  60% 
of patients with a composite end point 
of death and/or prolonged (>2days) 
ICU stay in the control group and  40% 
of patients in the treatment group. (18) 
We calculate that we will need a sample 
size of 97 patients per group. We plan 
to randomly select 200 patients in order 
to take into account possible protocol 
deviations. All 200 patients will be anal-
ysed according to the intention-to-treat 
principle, beginning immediately after 
randomization.
Monitoring of the study
Monitors will verify adherence to requ-
ired clinical trial procedures and con-
firm accurate collection of data and 
will follow the Good Clinical Practice 
(GCP) guidelines. Study monitoring 
and follow-up, from the initial set-up to 
final reporting, will be fulfilled according 
to current National and International 
requirements.
Timing
The study will be concluded within 2 
years after the first randomization.
Ethical aspects
Both anesthesia plans represent stan-
dard management for modern cardiac 
anesthesia. They have similar costs 
and result in the same haemodynamic 
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stability. They are both easily performed 
and all cardiac anesthesiologists can 
perform them. No risk for the study 
subjects is expected. Today there is 
still no evidence that high risk patients 
could benefit from volatile anesthetics.
No interference with subject privacy is 
planned. Data will be stored in an elec-
tronic database without indicating the 
name of the patients (a numeric code 
will be used).
Expected results
During the planned study we will test 
the hypothesis that volatile anestheti-
cs could reduce cardiac damage and 
allow for better tissue perfusion and 
faster recovery. Our trial could help in 
determining whether these drugs, used 
in cardiac anesthesia, improve outco-
mes and reduce hospital costs. For this 
reason, high risk patients with planned 
combined valvular and coronary sur-
gery will be enrolled in a multicentre 
controlled study and randomized to 
receive either total intravenous ane-
sthesia with propofol or anesthesia with 
sevoflurane. 
Discussion
Cardioprotection by anesthetic drugs is 
a topical matter in cardiac anesthesia. 
Many studies (11-16,18,19) and reviews 
(21-22) have appeared in the literatu-
re suggesting a cardioprotective effect 
provided by volatile anesthetics in pati-
ents undergoing cardiac procedures.
A recent survey (23) conducted in 64 
Italian centres, encompassing a total of 
34,310 patients undergoing coronary 
artery bypass graft surgery, showed 
that risk-adjusted mortality may be 
reduced by the use of volatile agents. 
Furthermore, a longer use of volati-
le anesthetics was associated with a 
significantly lower death rate. 
Volatile anesthetics were considered 
among the few drugs that could reduce 
perioperative mortality in cardiac surge-
ry and that deserve further studies by 
the first international consensus confe-
rence on mortality reduction in cardiac 
anesthesia and intensive care. (24)
However, data on high risk patients, 
such as those undergoing combined 
valvular and coronary surgery, are lac-
king. We will conduct a large multicen-
tre randomized study in these patients, 
administering sevoflurane throughout 
the whole procedure to address the 
question whether the choice of ane-
sthetic regimen might influence pati-
ents’ outcome after cardiac surgery.
Clinical implications could be exten-
ded to patients with coronary disease 
undergoing non-cardiac surgery. To 
this day there is no evidence that vola-
tile anesthetics could be cardioprotec-
tive in non-cardiac surgery. (25) On 
the contrary, a randomized study (26) 
showed that myocardial damage, mea-
sured by cardiac troponin release, was 
not reduced by the volatile anesthetic 
sevoflurane during interventional cardi-
ology procedures.
This will be the first multicentre rando-
mized controlled trial comparing the 
effects of volatile anesthetics and total 
intravenous anesthesia in high risk pati-
ents undergoing cardiac procedures. 
Evidence resulting from this study will 
be of primary importance in the ane-
sthesiological management of high risk 
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